Oncopeptides Logo

Oncopeptides

Biotech firm developing targeted therapies for hematological cancers.

ONCO | ST

Overview

Corporate Details

ISIN(s):
SE0009414576 (+4 more)
LEI:
549300J9WWQ5CBYQ1M77
Country:
Sweden
Address:
Luntmakargatan 46, 111 37 Stockholm

Description

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 08:30
Oncopeptides har utsett valberedningen
Swedish 63.1 KB
2025-11-21 08:30
Oncopeptides announces the Nomination Committee
English 62.7 KB
2025-11-05 08:00 Swedish 550.9 KB
2025-11-05 08:00 English 636.0 KB
2025-10-31 08:30
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-10-31 08:30
Number of shares and votes in Oncopeptides
English 67.6 KB
2025-10-28 09:37 Swedish 10.4 KB
2025-10-13 18:45
Oncopeptides issues warrants to fulfil its obligations under loan agreement wit…
English 76.0 KB
2025-10-13 18:45
Oncopeptides emitterar teckningsoptioner för att uppfylla sina skyldigheter und…
Swedish 76.7 KB
2025-10-10 13:36 Swedish 10.8 KB
2025-10-08 09:50 Swedish 10.5 KB
2025-09-30 10:00
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-09-30 10:00
Number of shares and votes in Oncopeptides
English 67.7 KB
2025-09-17 08:30
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
English 86.0 KB
2025-09-17 08:30
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Swedish 86.2 KB

Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncopeptides

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncopeptides via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-15 David Augustsson Other Buy 1,250 6,350.00 SEK
2024-04-15 David Augustsson Other Buy 1,250 6,312.50 SEK
2024-04-15 David Augustsson Other Buy 438 2,225.04 SEK
2024-04-15 David Augustsson Other Buy 60 303.60 SEK
2024-04-15 David Augustsson Other Buy 2 10.02 SEK
2023-09-08 David Augustsson Other Buy 2,296 17,706.75 SEK
2023-08-10 David Augustsson Other Buy 1,704 14,995.20 SEK
2023-05-04 Nicolaas Bakker Other Buy 5,000 42,380.00 SEK
2022-10-10 Nicolaas Bakker Other Buy 15,000 164,400.00 SEK
2022-08-30 Per Wold-Olsen Other Buy 2,050 55,350.00 SEK

Peer Companies

Denali Therapeutics Inc. Logo
Develops therapies for neurodegenerative diseases using a blood-brain barrier platform.
United States of America
DNLI
Dermapharm Holding SE Logo
A manufacturer of patent-free branded pharmaceuticals and healthcare products.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Medical dermatology company developing and commercializing OTC skin care products.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops therapeutics for serious diseases using innovative blood biomarkers.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Develops, produces, and markets human medicines, APIs, and veterinary drugs globally.
Spain
DEVA
Devyser Diagnostics Logo
Develops DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring.
Sweden
DVYSR
DexTech Medical AB Logo
Develops drug candidates for urological oncology, focusing on prostate cancer.
Sweden
DEX
DiaMedica Therapeutics Inc. Logo
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
A clinical-stage company developing precision therapies for autoimmune diabetes.
Sweden
DMYD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.